This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients
Able to do routine blood testing (normal care for transplant recipients)
Written informed consent obtained from the subject before any trial-related procedures
Be ≥18 years and ≤75 years of age at time of consent
Any pre-transplant CMV serologic combinations besides CMV D+/R-
Multi organ transplants (other than simultaneous liver-kidney transplant (SLK) recipients) or prior history of bone marrow or stem cell transplant
Lung, heart, small bowel, pancreas, or other non-kidney or non-liver transplant recipients
Transplant recipients treated for rejection within three months before the end of valganciclovir prophylaxis
Camille N. Kotton, MD
Lead sponsor
Massachusetts General Hospital
Sponsor institution
University of Texas Southwestern Medical Center
Collaborator
Kamada, Ltd.
Collaborator